Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy.

Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, 
Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A

Division of Neurology, 
Ottawa General Hospital, ON, Canada
Neurology 1997 Aug;49(2):444-51

ABSTRACT

Seventy-five patients meeting international diagnostic criteria for narcolepsy enrolled in a 6-week, three-period, randomized, crossover, placebo-controlled trial. Patients received placebo, modafinil 200 mg, or modafinil 400 mg in divided doses (morning and noon). Evaluations occurred at baseline and at the end of each 2-week period. Compared with placebo, modafinil 200 and 400 mg significantly increased the mean sleep latency on the Maintenance of Wakefulness Test by 40% and 54%, with no significant difference between the two doses. Modafinil, 200 and 400 mg, also reduced the combined number of daytime sleep episodes and periods of severe sleepiness noted in sleep logs. The likelihood of falling asleep as measured by the Epworth Sleepiness Scale was equally reduced by both modafinil dose levels. There were no effects on nocturnal sleep initiation, maintenance, or architecture, nor were there any effects on sleep apnea or periodic leg movements. Neither dose interfered with the patients' ability to nap voluntarily during the day nor with their quantity or quality of nocturnal sleep. Modafinil produced no changes in blood pressure or heart rate in either normotensive or hypertensive patients. The only significant adverse effects were seen at the 400-mg dose, which was associated with more nausea and more nervousness than either placebo or the 200-mg dose. As little as a 200-mg daily dose of modafinil is therefore an effective and well-tolerated treatment of excessive daytime somnolence in narcoleptic persons.

 1.   Modafinil  for sustaining the alertness of helicopter pilots
 2.   Modafinil  augmentation of antidepressant treatment
 3.   Modafinil  the unique properties of a new stimulant 
 4.   Modafinil  children with attention-deficit/hyperactivity disorder
 5.   Modafinil  dosage and safety
 6.   Modafinil  successful treatment of hypersomnia & narcolepsy
 7.   Modafinil  narcolepsy: symptoms and management
 8.   Modafinil  amplification of cortical serotonin release
 9.   Modafinil  treatment of alcoholic organic brain syndrome
10.  Modafinil  effect on melatonin, cortisol, and growth hormone
11.  Modafinil  in obstructive sleep apnea-hypopnea syndrome
12.  Modafinil  vs dextroamphetamine in treatment of adult ADHD
13.  Modafinil  efficacy in narcolepsy
14.  Modafinil  switching from narcolepsy drugs to modafinil
15.  Modafinil  dopaminergic transmission mediates CNS stimulants

| Home | Order |
www.AlzheimersTreatments.com